Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Design Therapeutics, Inc.NASDAQ: DSGN
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 61.43M shares rose 8.2% year over year, ahead of the +2.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.2% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.2% holds above the trailing-twelve-month pace of +2.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 57.33M USD
- Year-over-year change
- +1.3%
- 4-year CAGR
- +5.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.33M | +1.3% |
| FY2024 | 2024-12-31 | 56.59M | +1.1% |
| FY2023 | 2023-12-31 | 55.98M | +0.5% |
| FY2022 | 2022-12-31 | 55.71M | +21.3% |
| FY2021 | 2021-12-31 | 45.94M | — |
Weighted Avg Shares (Diluted) vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 weighted avg shares (diluted) of 58.14M shares is the 10th highest of the 11 companies compared; the peer median is 91.93M shares.
- Its year-over-year change of +2.6% is the 10th highest of 11, against a peer median of +12.1%.
- Over three fiscal years its annual growth of +1.0% compares with a peer median of +21.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 178.01M | +19.3% | +28.8% | |
| LTM Sep 2026 | 164.62M | -0.2% | +4.1% | |
| LTM Jun 2026 | 150.19M | +40.8% | +35.2% | |
| LTM Mar 2026 | 108.39M | +6.9% | +6.2% | |
| LTM Mar 2026 | 98.28M | +94.3% | +117.4% | |
| LTM Jun 2026 | 85.59M | +7.4% | +7.2% | |
| LTM Mar 2026 | 78.18M | +22.5% | +41.5% | |
| LTM Mar 2026 | 66.18M | +9.2% | +12.1% | |
| LTM Mar 2026 | 59.6M | +4.3% | +15.0% | |
| LTM Mar 2026 | 58.14M | +2.6% | +1.0% | |
| LTM Mar 2026 | 37.49M | +15.0% | +39.2% | |
| Peer median (excluding DSGN) | 91.93M | +12.1% | +21.9% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.